About our charity partners
ANZGOG is the peak, national gynaecological cancer clinical trials organisation for Australia and New Zealand.
Their purpose is to improve outcomes and quality of life for women with gynaecological cancer through conducting and promoting cooperative clinical trials and undertaking multidisciplinary research into the causes, prevention and treatments of gynaecological cancer.
ANZGOG was established in 2000. Their 940+ members include clinicians who treat women with gynaecological cancer, nurses, laboratory researchers and women with cancer. They conduct research with over 52 hospitals and many research and academic institutions. ANZGOG is active in all states and most territories of Australia; and New Zealand.
Visit our ANZGOG donation page on our Australian website to make a donation directly to their low-grade serous research programme.
BC Cancer Foundation
The BC Cancer Foundation is the fundraising partner of BC Canada and the largest charitable funder of cancer research in British Columbia. With BC Canada Foundation's support, BC Cancer's world-leading ovarian cancer research (OVCARE) team is advancing prevention, diagnosis and treatment for all women facing gynecological cancers including low-grade serous ovarian cancer.
Over the past few years, an OVCARE research team, led by Dr. Mark Carey, has made significant progress in the search for better treatments for women facing low-grade serous ovarian cancer. They are the largest and most experienced low grade serous research group in Canada.
GRACI Foundation (Gynaecological Cancer Research and Clinical Innovation)
The Graci Foundation was established to improve outcomes for women suffering from a gynaecological cancer by supporting New Zealand based research. The trustees know that research is the key to progress; and are passionate to see women with low-grade serous ovarian cancer benefit from the latest advancements in the field.
Edinburgh Cancer Research Centre
The Cancer Research UK Edinburgh Centre brings together cancer scientists and clinicians from across the University of Edinburgh delivering outstanding cancer research. The co-located Edinburgh Cancer Centre provides cutting-edge oncological patient care to a quarter of the Scottish population.
Ovarian cancer is one of the research priority tumours for the Cancer Research UK Edinburgh Centre. The research is carried out by Professor Charlie Gourley in the Nicola Murray Centre for Ovarian Cancer Research. His team have provided national leadership on low grade serous ovarian cancer clinical trials and are now performing laboratory research to inform the next generation of low grade serous ovarian cancer clinical trials.
The University of Texas MD Anderson Cancer Center
The University of Texas MD Anderson Cancer Center in Houston is one of the world's most respected centers focused on cancer patient care, research, education and prevention. It was named the nation's No. 1 hospital for cancer care in U.S. News World Report 2018 rankings.
It is one of the nation's original three comprehensive cancer centers designated by the National Cancer Institute. Since 1944, more than 1.2 million patients have sought out MD Anderson’s expertise.
The institution pioneered a multidisciplinary approach to research-driven care. Their researchers include Dr David Gershenson who is widely considered to be the world expert on low-grade serous ovarian cancer. Research carried out by the MD Anderson Cancer Center has helped form many of the current treatment recommendations for women with low-grade serous ovarian cancer.
To make a donation to their low-grade research program please visit our United States website for instructions.
Memorial Sloan Kettering Cancer Center - the world’s oldest and largest private cancer center - has devoted more than 130 years to exceptional patient care, innovative research, and outstanding educational programs.
Today it is one of 50 National Cancer Institute–designated Comprehensive Cancer Centers, with state-of-the-art science flourishing side by side with clinical studies and treatment. The close collaboration between MSK's physicians and scientists is one of its unique strengths, enabling it to provide patients with the best care available as researchers work to discover more effective strategies to prevent, control, and ultimately cure cancer in the future.
U.S. News World Report has ranked Memorial Sloan Kettering Cancer Center (MSK) as one of the top hospitals for cancer care in the nation, and the top cancer center in the northeast, in its annual listing of Best Hospitals.
This year, 2019, MSK is also ranked #1 in the nation for gynecological cancer care—an extraordinary recognition of excellence that reflects the deep commitment and expertise of our specialists who care for patients with cervical, uterine (endometrial), or ovarian cancer. Beyond treating patients at MSK, our team has pioneered many advances that are now the standard of care worldwide.
Learn more about MSKCC's low-grade serous research on our US website.